arrow
M

Marı́a José Calasanz

cun and navarra institute for health research
H指数:63
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring the synergy between telomere length and genomic complexity in CLL

探索端粒长度与基因组复杂性在CLL中的协同作用

2026-01-230
OAAI
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma

微小残留病灶动态预测进展并揭示多发性骨髓瘤中免疫治疗干预的易感状态

Blood
IF23.1
2026-01-010
PRE
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia

RAS突变在急性髓系白血病中的基因组学和临床景观

Blood
IF23.1
2026-01-010
PRE
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

高剂量白消安-美法仑 vs 美法仑及强化VRD方案用于新诊断多发性骨髓瘤:一项GEM III期试验

Blood
IF23.1
2025-06-140
PRE
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

新诊断多发性骨髓瘤早期复发的危险因素:细胞遗传学和初始治疗反应的影响

2025-04-240
OAAI
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

t(11;14)是否总是一种标准风险细胞遗传学异常?GEM05MENOS65和GEM2012 PETHEMA/GEM移植试验的结果。

2025-01-250
PRE
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

初诊多发性骨髓瘤患者Bcl-2家族蛋白表达谱分析

2024-12-130
OAAI
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

多发性骨髓瘤的高风险细胞遗传学异常: petema-GEM经验

2024-12-100
OAAI
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome inpatients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

通过质谱分析周围残留疾病的单点和动力学,以预测gem-cesar试验中包括的高危阴燃性多发性骨髓瘤患者的结局

2024-07-110
OAAI
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
2024-07-022
OAAI
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

用强化策略治疗的高危阴燃骨髓瘤患者的基因组分析揭示了耐药和进展的潜在标志物

2024-04-290
OAAI
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
2023-08-312
OAAI
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
2023-05-128
OAAI
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

用于预测遗传异质性多发性骨髓瘤的免疫治疗结果和免疫逃避机制的临床前模型

2023-03-1628
OAAI
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Dec, 10.1038/s41375-022-01802-y, 2022)
LEUKEMIA
IF13.4
2023-01-121
OAAI
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
2023-01-104
OAAI